Rebamipide hydrate
SIGMA/R5655 - ≥98% (HPLC), powder
Synonym: α-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic acid hydrate; Mucosta hydrate; OPC 12759 hydrate; Proamipide hydrate
CAS Number: 90098-04-7 (anhydrous)
Empirical Formula (Hill Notation): C19H15ClN2O4 · xH2O
Molecular Weight: 370.79 (anhydrous basis)
MDL Number: MFCD11114396
Linear Formula: C19H15ClN2O4 · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | powder |
| InChI | 1S/C19H15ClN2O4.H2O/c20-1 |
| InChI key | WQRHVBKNEDPECA-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | O.OC(=O)C(CC1=CC(=O)Nc2cc |
| solubility | DMSO: >5 mg/mL |
| Biochem/physiol Actions: | Rebamipide hydrate is an anti-ulcer agent, an antioxidant, a gastrointestinal agent, and a gastric cytoprotectant. |
| Biochem/physiol Actions: | Rebamipide is an anti-ulcer agent with free-radical scavenging and anti-inflammatory effects. It has been used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating COX-2 genes. Rebamipide significantly reduced ulcerogenesis and maintained mucosal superoxide dismutase (SOD) activity. It has also been used for the treatment of Behçet′s disease. Rebamipide may be involved in a noval mechanism to enhance tear secretion and increase mucin levels covering conjunctiva and cornea. |
| Biochem/physiol Actions: | Rebamipide helps to reduce intestinal injury, stimulated by radiation. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H301 |
| Precautionary statements | P301 + P310 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |


